{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:32:54Z","timestamp":1777894374292,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.xphs.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:58:59Z","timestamp":1592481539000},"page":"2919-2924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of the Interaction of Daptomycin With Site II on Human Serum Albumin"],"prefix":"10.1016","volume":"109","author":[{"given":"Keishi","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiki","family":"Sakurama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakaru","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"SUPPL. 1","key":"10.1016\/j.xphs.2020.06.011_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1469-0691.2006.01342.x","article-title":"The efficacy and safety of daptomycin: first in a new class of antibiotics for gram-positive bacteria","volume":"12","author":"Rybak","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"24","key":"10.1016\/j.xphs.2020.06.011_bib2","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","article-title":"The action mechanism of daptomycin","volume":"24","author":"Taylor","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.xphs.2020.06.011_bib3","series-title":"Daptomycin","author":"Patel","year":"2019"},{"issue":"1","key":"10.1016\/j.xphs.2020.06.011_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2020.06.011_bib5","series-title":"Antibiotic Pharmacokinetic\/Pharmacodynamic Considerations in the Critically Ill","author":"Udy","year":"2017"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.011_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.xphs.2020.06.011_bib7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1128\/AAC.35.12.2505","article-title":"Effect of protein binding of daptomycin on MIC and antibacterial activity","volume":"35","author":"Lee","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.xphs.2020.06.011_bib8","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/j.bbagen.2013.05.005","article-title":"Albumin-drug interaction and its clinical implication","volume":"1830","author":"Yamasaki","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2020.06.011_bib9","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland","year":"2011"},{"issue":"6","key":"10.1016\/j.xphs.2020.06.011_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJM197602052940605","article-title":"Binding of drugs to serum albumin (first of two parts)","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.xphs.2020.06.011_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/AAC.34.10.1925","article-title":"Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in\u00a0vitro pharmacodynamic model","volume":"34","author":"Garrison","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2007.11.011","article-title":"Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum","volume":"60","author":"Tsuji","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"39","key":"10.1016\/j.xphs.2020.06.011_bib13","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1021\/acs.jpcb.8b07503","article-title":"A\u00a0quantitative model of daptomycin binding to lipid bilayers","volume":"122","author":"Pokorny","year":"2018","journal-title":"J\u00a0Phys Chem B"},{"issue":"Pt 1","key":"10.1016\/j.xphs.2020.06.011_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/bj3570269","article-title":"Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants","volume":"357","author":"Watanabe","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.xphs.2020.06.011_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1042\/bj3490813","article-title":"Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity","volume":"819","author":"Watanabe","year":"2000","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.xphs.2020.06.011_bib16","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1021\/bi00279a018","article-title":"Resonance energy transfer between cysteine-34, tryptophan-214, and tyrosine-411 of human serum albumin","volume":"22","author":"Hagag","year":"1983","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.xphs.2020.06.011_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0026-895X(25)14450-7","article-title":"Structural requirements for drug binding to site II on human serum albumin","volume":"24","author":"Wanwimolruk","year":"1983","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.xphs.2020.06.011_bib18","series-title":"All about Albumin: Biochemistry, Genetics, and Medical Applications","author":"Peters","year":"1995"},{"issue":"3","key":"10.1016\/j.xphs.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin\u00a0: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol Aspects Med"},{"issue":"1","key":"10.1016\/j.xphs.2020.06.011_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)00015-8","article-title":"Drug binding to human alpha-1-acid glycoprotein in health and disease","volume":"40","author":"Kremer","year":"1988","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.xphs.2020.06.011_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/acsinfecdis.7b00015","article-title":"Plasma protein binding structure-activity relationships related to the N-terminus of daptomycin","volume":"3","author":"Schneider","year":"2017","journal-title":"ACS Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2020.06.011_bib24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.25011\/cim.v33i6.14589","article-title":"HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations","volume":"33","author":"Bryan","year":"2010","journal-title":"Clin Invest Med"},{"issue":"6134","key":"10.1016\/j.xphs.2020.06.011_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/bmj.2.6134.388","article-title":"Severity of coronary atherosclerosis related to lipoprotein concentration","volume":"2","author":"Nestel","year":"1978","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.011_bib26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni911","article-title":"Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections","volume":"4","author":"Hunziker","year":"2003","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2133\/dmpk.24.342","article-title":"Lessons from the crystallographic analysis of small molecule binding to human serum albumin","volume":"24","author":"Curry","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.xphs.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1248\/bpb.25.695","article-title":"Practical aspects of the ligand-binding and enzymatic properties of human serum albumin","volume":"25","author":"Kragh-Hansen","year":"2002","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.xphs.2020.06.011_bib29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J\u00a0Mol Biol"},{"issue":"8","key":"10.1016\/j.xphs.2020.06.011_bib30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bbapap.2017.04.004","article-title":"Crystallographic analysis of the ternary complex of octanoate and N-acetyl-l-methionine with human serum albumin reveals the mode of their stabilizing interactions","volume":"1865","author":"Kawai","year":"2017","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10.1016\/j.xphs.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"13790","DOI":"10.1021\/acsomega.8b02057","article-title":"Analysis of the binding of aripiprazole to human serum albumin: the importance of a chloro-group in the chemical structure","volume":"3","author":"Sakurama","year":"2018","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.011_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1023\/A:1011014629551","article-title":"Indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin","volume":"18","author":"Sakai","year":"2001","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2020.06.011_bib33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bbapap.2017.04.004","article-title":"Crystallographic analysis of the ternary complex of octanoate and N -acetyl- l -methionine with human serum albumin reveals the mode of their stabilizing interactions","volume":"1865","author":"Kawai","year":"2017","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"9","key":"10.1016\/j.xphs.2020.06.011_bib34","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1021\/bi301458b","article-title":"Correspondence of fatty acid and drug binding sites on human serum albumin: a two-dimensional nuclear magnetic resonance study","volume":"52","author":"Krenzel","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.xphs.2020.06.011_bib35","unstructured":"U.S. Food and Drug Administration. FDA Label of Cubicin\u00ae."},{"key":"10.1016\/j.xphs.2020.06.011_bib36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jmb.2008.06.016","article-title":"Crystallographic analysis of human serum albumin complexed with 4Z, 15E-Bilirubin-Ix\u03b1","volume":"381","author":"Zunszain","year":"2008","journal-title":"J\u00a0Mol Biol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920303233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920303233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:30:07Z","timestamp":1758360607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920303233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0022354920303233"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.06.011","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the Interaction of Daptomycin With Site II on Human Serum Albumin","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}